Plus Therapeutics (PSTV) appointed Michael Rosol as Chief Development Officer. Rosol will lead the company’s clinical, pre-clinical, and biomarker development activities. Rosol most recently served as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals. Prior to his most recent role, Rosol worked at Novartis Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV: